Macrovascular Complications.
Where this comes from
- Record sourced from PubMed, PMID 35595481.
- Also identified by DOI 10.1016/j.pop.2021.11.012.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Because macrovascular complications of diabetes are the leading cause of mortality and decreased quality of life for individuals with diabetes, prevention and risk reduction are paramount. Besides lifestyle management, contemporary therapies can significantly reduce risk for cardiovascular events in diabetes. For primary prevention, most individuals should be on statin therapy, whereas those at high atherosclerotic cardiovascular disease risk should also be on glucagon-like peptide 1 receptor agonists (GLP1RA) or sodium/glucose cotransporter-2 inhibitors (SGLT2i) at any hemoglobin A1c. For secondary prevention, addition of GLP1RA or SGLT2i, PCKS9i, rivaroxaban, and/or icosapent ethyl should be considered in addition to a statin and low-dose aspirin.
Medical subject headings
- Cardiovascular Diseases
- Diabetes Mellitus, Type 2
- Hydroxymethylglutaryl-CoA Reductase Inhibitors
- Sodium-Glucose Transporter 2 Inhibitors